A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
Protagonist “delighted” with trial failure
Development of the ulcerative colitis project PN-943 continues.
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Roche has a rare breast cancer setback
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
